First Manhattan’s Lucid Diagnostics LUCD Stock Holding History

First Manhattan’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.34M	Buy	2,188,550 +1,865,100	+577%	+$2.01M	0.01%	332
2026 Q1	$372K	Hold	323,450	–	–	﹤0.01%	622
2025 Q4	$353K	Hold	323,450	–	–	﹤0.01%	619
2025 Q3	$327K	Hold	323,450	–	–	﹤0.01%	610
2025 Q2	$372K	Buy	323,450 +310,850	+2,467%	+$401K	﹤0.01%	584
2025 Q1	$18.8K	Hold	12,600	–	–	﹤0.01%	675
2024 Q4	$10.3K	Hold	12,600	–	–	﹤0.01%	679
2024 Q3	$10.3K	Hold	12,600	–	–	﹤0.01%	680
2024 Q2	$10.3K	Buy	+12,600	New	+$10.7K	﹤0.01%	667

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

First Manhattan's LUCD Position: Q2 2026 in Review

First Manhattan increased its Lucid Diagnostics (LUCD) stake by 577% in Q2 2026, buying an estimated $2.01M and bringing the position to 2,188,550 shares worth $2.34M. The position accounts for 0.01% of the portfolio, ranked #332.

First Manhattan first reported a position in LUCD in Q2 2024 and has held it in 9 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

First Manhattan held 2,188,550 shares of Lucid Diagnostics worth $2.34M as of Q2 2026.
First Manhattan bought 1,865,100 Lucid Diagnostics shares in Q2 2026, an estimated $2.01M.
Lucid Diagnostics made up 0.01% of First Manhattan's portfolio in Q2 2026, its #332 holding.
First Manhattan first reported a position in Lucid Diagnostics in Q2 2024 and has held it in 9 quarters since.
116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on First Manhattan's 13F filing for Q2 2026, filed 14 Aug 2026.